Passive and active antibody studies in primates to inform HIV vaccines

Ann Hessell, Delphine Malherbe, Nancy Haigwood

    Research output: Contribution to journalReview article

    5 Citations (Scopus)

    Abstract

    Introduction: Prevention of infection remains the ultimate goal for HIV vaccination, and there is compelling evidence that antibodies directed to Envelope are necessary to block infection. Generating antibodies that are sufficiently broad, potent, and sustained to block infection by the diverse HIV-1 strains circulating worldwide remains an area of intense study. Areas covered: In this review, we have summarized progress from publications listed as PubMed citations in 2016–17 in the areas of passive antibody studies using human neutralizing monoclonal antibodies in nonhuman primates, HIV Envelope vaccine development and active vaccination studies to generate potent neutralizing antibodies. Expert commentary: Passive transfer studies in nonhuman primates using human neutralizing monoclonal antibodies have informed the potency, specificity, and cooperativity of antibodies needed to prevent infection, leading to clinical studies now testing potent antibodies for prevention of HIV. Progress in understanding the structure of Envelope has led to novel vaccine constructs, including mimetics, scaffolds and native-like proteins. As yet, no single approach ensures protection against the circulating global HIV-1 strains, but there is progress in understanding why, and intense research continues in these and other areas for a solution. We offer perspectives on how this knowledge may shape the design of future HIV vaccines.

    Original languageEnglish (US)
    Pages (from-to)127-144
    Number of pages18
    JournalExpert Review of Vaccines
    Volume17
    Issue number2
    DOIs
    StatePublished - Feb 1 2018

    Fingerprint

    AIDS Vaccines
    Primates
    Neutralizing Antibodies
    Antibodies
    Infection
    HIV-1
    Vaccination
    Monoclonal Antibodies
    HIV Antibodies
    Antibody Specificity
    PubMed
    Publications
    Vaccines
    HIV
    Research
    Proteins

    Keywords

    • antibodies
    • Envelope
    • HIV
    • monoclonal antibodies
    • passive
    • protective efficacy
    • vaccines

    ASJC Scopus subject areas

    • Immunology
    • Molecular Medicine
    • Pharmacology
    • Drug Discovery

    Cite this

    Passive and active antibody studies in primates to inform HIV vaccines. / Hessell, Ann; Malherbe, Delphine; Haigwood, Nancy.

    In: Expert Review of Vaccines, Vol. 17, No. 2, 01.02.2018, p. 127-144.

    Research output: Contribution to journalReview article

    @article{a69c33dc2b4f4cdf847428e88378d0b5,
    title = "Passive and active antibody studies in primates to inform HIV vaccines",
    abstract = "Introduction: Prevention of infection remains the ultimate goal for HIV vaccination, and there is compelling evidence that antibodies directed to Envelope are necessary to block infection. Generating antibodies that are sufficiently broad, potent, and sustained to block infection by the diverse HIV-1 strains circulating worldwide remains an area of intense study. Areas covered: In this review, we have summarized progress from publications listed as PubMed citations in 2016–17 in the areas of passive antibody studies using human neutralizing monoclonal antibodies in nonhuman primates, HIV Envelope vaccine development and active vaccination studies to generate potent neutralizing antibodies. Expert commentary: Passive transfer studies in nonhuman primates using human neutralizing monoclonal antibodies have informed the potency, specificity, and cooperativity of antibodies needed to prevent infection, leading to clinical studies now testing potent antibodies for prevention of HIV. Progress in understanding the structure of Envelope has led to novel vaccine constructs, including mimetics, scaffolds and native-like proteins. As yet, no single approach ensures protection against the circulating global HIV-1 strains, but there is progress in understanding why, and intense research continues in these and other areas for a solution. We offer perspectives on how this knowledge may shape the design of future HIV vaccines.",
    keywords = "antibodies, Envelope, HIV, monoclonal antibodies, passive, protective efficacy, vaccines",
    author = "Ann Hessell and Delphine Malherbe and Nancy Haigwood",
    year = "2018",
    month = "2",
    day = "1",
    doi = "10.1080/14760584.2018.1425619",
    language = "English (US)",
    volume = "17",
    pages = "127--144",
    journal = "Expert Review of Vaccines",
    issn = "1476-0584",
    publisher = "Expert Reviews Ltd.",
    number = "2",

    }

    TY - JOUR

    T1 - Passive and active antibody studies in primates to inform HIV vaccines

    AU - Hessell, Ann

    AU - Malherbe, Delphine

    AU - Haigwood, Nancy

    PY - 2018/2/1

    Y1 - 2018/2/1

    N2 - Introduction: Prevention of infection remains the ultimate goal for HIV vaccination, and there is compelling evidence that antibodies directed to Envelope are necessary to block infection. Generating antibodies that are sufficiently broad, potent, and sustained to block infection by the diverse HIV-1 strains circulating worldwide remains an area of intense study. Areas covered: In this review, we have summarized progress from publications listed as PubMed citations in 2016–17 in the areas of passive antibody studies using human neutralizing monoclonal antibodies in nonhuman primates, HIV Envelope vaccine development and active vaccination studies to generate potent neutralizing antibodies. Expert commentary: Passive transfer studies in nonhuman primates using human neutralizing monoclonal antibodies have informed the potency, specificity, and cooperativity of antibodies needed to prevent infection, leading to clinical studies now testing potent antibodies for prevention of HIV. Progress in understanding the structure of Envelope has led to novel vaccine constructs, including mimetics, scaffolds and native-like proteins. As yet, no single approach ensures protection against the circulating global HIV-1 strains, but there is progress in understanding why, and intense research continues in these and other areas for a solution. We offer perspectives on how this knowledge may shape the design of future HIV vaccines.

    AB - Introduction: Prevention of infection remains the ultimate goal for HIV vaccination, and there is compelling evidence that antibodies directed to Envelope are necessary to block infection. Generating antibodies that are sufficiently broad, potent, and sustained to block infection by the diverse HIV-1 strains circulating worldwide remains an area of intense study. Areas covered: In this review, we have summarized progress from publications listed as PubMed citations in 2016–17 in the areas of passive antibody studies using human neutralizing monoclonal antibodies in nonhuman primates, HIV Envelope vaccine development and active vaccination studies to generate potent neutralizing antibodies. Expert commentary: Passive transfer studies in nonhuman primates using human neutralizing monoclonal antibodies have informed the potency, specificity, and cooperativity of antibodies needed to prevent infection, leading to clinical studies now testing potent antibodies for prevention of HIV. Progress in understanding the structure of Envelope has led to novel vaccine constructs, including mimetics, scaffolds and native-like proteins. As yet, no single approach ensures protection against the circulating global HIV-1 strains, but there is progress in understanding why, and intense research continues in these and other areas for a solution. We offer perspectives on how this knowledge may shape the design of future HIV vaccines.

    KW - antibodies

    KW - Envelope

    KW - HIV

    KW - monoclonal antibodies

    KW - passive

    KW - protective efficacy

    KW - vaccines

    UR - http://www.scopus.com/inward/record.url?scp=85042398189&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85042398189&partnerID=8YFLogxK

    U2 - 10.1080/14760584.2018.1425619

    DO - 10.1080/14760584.2018.1425619

    M3 - Review article

    VL - 17

    SP - 127

    EP - 144

    JO - Expert Review of Vaccines

    JF - Expert Review of Vaccines

    SN - 1476-0584

    IS - 2

    ER -